See more : Buyer Group International, Inc. (BYRG) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaCyte Biotech, Inc. (PMCB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaCyte Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Axiata Group Berhad (AXXTF) Income Statement Analysis – Financial Results
- Welcia Holdings Co., Ltd. (WLCGF) Income Statement Analysis – Financial Results
- Gentex Corporation (GNTX) Income Statement Analysis – Financial Results
- Genetron Holdings Limited (GTH) Income Statement Analysis – Financial Results
- COSMOS Pharmaceutical Corporation (CSMYF) Income Statement Analysis – Financial Results
PharmaCyte Biotech, Inc. (PMCB)
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.16K | 66.56K | 126.00K | 262.93K | 653.13K | 1.19M | 1.17M | 537.04K | 86.37K | 2.38K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.62K | 19.38K | 32.10K | 228.66K | 427.41K | 266.20K | 171.01K | 0.00 | 41.40K | 780.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K | 47.18K | 93.89K | 34.27K | 225.72K | 923.75K | 998.65K | 537.04K | 44.97K | 1.60K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.89% | 70.88% | 74.52% | 13.03% | 34.56% | 77.63% | 85.38% | 100.00% | 52.07% | 67.27% | 0.00% | 0.00% |
| Research & Development | 407.43K | 468.54K | 690.94K | 916.25K | 301.22K | 460.05K | 2.00M | 1.18M | 1.41M | 3.48M | 323.50 | 0.00 | 0.00 | 9.21K | 492.46K | 473.51K | 412.88K | 133.84K | 119.01K | 1.11M | 1.41M | 0.00 | 0.00 |
| General & Administrative | 4.79M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 9.99M | 18.11M | 1.58M | 1.99M | 462.22K | 1.24M | 5.20M | 0.00 | 0.00 | 6.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 230.50K | 872.20K | 106.41K | 11.15K | 10.83K | 411.72K | 594.34K | 0.00 | 0.00 | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.12M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 10.22M | 18.98M | 1.69M | 2.00M | 473.05K | 1.65M | 5.79M | 4.26M | 4.47M | 7.75M | 3.10M | 313.95K | 32.13K | 0.00 |
| Other Expenses | 0.00 | 202.00K | -4.28K | -1.19K | -40.00 | 33.40K | 152.59K | 2.52M | 10.54K | 3.34M | -5.90M | 2.59K | 1.22M | 103.90K | 0.00 | 4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.85K |
| Operating Expenses | 8.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.69M | 2.00M | 482.25K | 2.14M | 6.27M | 4.67M | 4.61M | 7.87M | 4.21M | 1.72M | 32.13K | 29.85K |
| Cost & Expenses | 6.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.70M | 2.02M | 514.36K | 2.37M | 6.70M | 4.94M | 4.78M | 7.87M | 4.25M | 1.72M | 32.13K | 29.85K |
| Interest Income | 3.40M | 1.94M | 157.65K | 3.05 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 0.00 | 0.00 | 0.00 | 0.00 | 14.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 509.00 | 3.05K | 453.00 | 0.00 | 0.00 | 1.54K | 1.19K | 4.94K | 21.05K | 154.42K | 241.25K | 171.66K | 292.56K | 27.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 492.05K | -5.89M | 2.59K | 24.66K | 40.69K | 114.91K | 28.83K | 6.38K | 1.35K | 488.00 | 23.26K | 0.00 | 0.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -3.83M | 0.00 | 0.00 | -4.44M | 0.00 | -9.92M | -27.23M | -1.68M | -1.63M | -388.36K | -2.11M | -5.99M | -3.78M | -3.61M | -7.33M | -1.72M | -1.73M | -32.13K | -29.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,830.35% | -3,328.88% | 388.91% | 607.14% | -922.67% | -308.99% | -308.83% | -1,049.52% | -4,810.34% | -72,213.26% | 0.00% | 0.00% |
| Operating Income | -6.52M | -6.46M | -4.39M | -3.62M | -3.83M | -4.10M | -6.98M | -4.44M | -6.07M | -13.70M | -18.98M | -1.68M | -1.95M | -388.36K | -2.11M | -6.04M | -3.75M | -3.61M | -7.34M | -4.16M | -1.72M | -32.13K | -29.85K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,851.65% | -2,928.55% | -308.23% | -802.09% | -925.09% | -315.07% | -308.42% | -1,365.85% | -4,819.57% | -72,213.26% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.85M | 2.14M | 152.85K | 71.75K | -493.00 | 33.40K | 152.59K | -1.54K | 9.35K | 2.84M | -8.27M | 86.26K | 49.87K | -837.69K | -3.88M | 471.00 | -42.72K | -6.79K | -1.76M | -114.04K | 1.73M | 0.00 | 0.00 |
| Income Before Tax | 333.76K | -4.32M | -4.24M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.66M | -1.23M | -5.70M | -6.03M | -3.82M | -3.60M | -9.03M | -4.15M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,491.16% | -973.08% | -2,167.62% | -923.10% | -320.62% | -307.90% | -1,682.09% | -4,801.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -153.36K | 3.05K | 453.00 | -33.40K | -152.59K | -4.44K | -4.88K | 4.94K | 19.96K | 154.42K | -49.87K | 1.01M | 3.88M | -471.00 | 42.72K | 6.79K | 2.05M | 114.04K | 1.72M | 32.13K | 29.85K |
| Net Income | 333.76K | -4.32M | -4.09M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.90M | -1.40M | -5.99M | -6.04M | -3.79M | -3.61M | -9.39M | -4.28M | -1.72M | -32.13K | -29.85K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,853.62% | -1,109.32% | -2,278.89% | -925.02% | -318.66% | -309.00% | -1,747.61% | -4,951.60% | -72,375.79% | 0.00% | 0.00% |
| EPS | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.89 | -12.09 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| EPS Diluted | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.88 | -12.08 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| Weighted Avg Shares Out | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 645.76K | 563.54K | 501.60K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
| Weighted Avg Shares Out (Dil) | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 646.08K | 563.82K | 501.85K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte has successfully completed a 36 month stability study on its Master Cell Bank cells that will be used for treatment of pancreatic cancer.
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the financial results for its second quarter ended October 31, 2021, and...
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech reports on its second quarter financial results and its operational highlights.
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of an additional, more detailed, analysis of the integration...
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech successfully complete the cytochrome P450 site of integration DNA sequencing assay required by the FDA to lift the clinical hold.
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the commencement of a pivotal study to determine if the treatment PharmaCyte...
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech launches its malignant ascites program with commencement of a pivotal preclinical study.
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that makes up its CypCaps™ pancreatic cancer...
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces that its clinical trial product material does not cause skin irritation passing another biocompatibility test.
3 Penny Stocks Waiting on FDA Approval for Rocket Fuel
Several penny stocks out there have done very well recently but these three biotechs are waiting for positive FDA news to soar higher. The post 3 Penny Stocks Waiting on FDA Approval for Rocket Fuel appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports